Shopping Cart
- Remove All
- Your shopping cart is currently empty
Dihydroquinoline-pyrazoline DQP-997-74 (compound 2i) is a selective N-methyl-d-aspartate receptor (NMDAR) inhibitor that preferentially targets GluN2C/D subunits, with IC50 values of 0.069 μM and 0.035 μM, respectively, and possesses blood-brain barrier permeability. It enhances its inhibitory potency in a time-dependent manner when combined with the agonist glutamate, reducing epileptogenic events in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 is potentially applicable for the study of NMDAR-related neurological diseases [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | Dihydroquinoline-pyrazoline DQP-997-74 (compound 2i) is a selective N-methyl-d-aspartate receptor (NMDAR) inhibitor that preferentially targets GluN2C/D subunits, with IC50 values of 0.069 μM and 0.035 μM, respectively, and possesses blood-brain barrier permeability. It enhances its inhibitory potency in a time-dependent manner when combined with the agonist glutamate, reducing epileptogenic events in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 is potentially applicable for the study of NMDAR-related neurological diseases [1]. |
Molecular Weight | 570.37 |
Formula | C28H19Cl2F2N3O4 |
Cas No. | 2377187-09-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.